

Nifedipine levels in Mothers with and without PreEclampsia and their Newborns.

Published: 28-09-2018

Last updated: 11-04-2024

Primary Objective: To compare the fetal/maternal ratio of nifedipine blood concentrations between pregnancies with and without hypertensive disorders, including preeclampsia. Secondary Objective: To compare predicted fetal/maternal drug ratios with...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Maternal complications of pregnancy
Study type	Observational invasive

Summary

ID

NL-OMON46737

Source

ToetsingOnline

Brief title

NIMPEN

Condition

- Maternal complications of pregnancy
- Vascular hypertensive disorders

Synonym

for instance preeclampsia, hypertensive pregnancy disorders

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Source(s) of monetary or material Support: Stichting De Merel

Intervention

Keyword: Hypertensive pregnancy disorder, Pharmacokinetics, Placental transfer

Outcome measures

Primary outcome

Concordance between the fetal/maternal ratio (both predicted and calculated) between pregnancies without and with hypertension or PE. Since variation is expected to be high, values <0.1 (limited transfer), $0.1-1$ (transfer) and >1 (fetal accumulation) will be considered as similar between both groups.

Secondary outcome

Concordance between the fetal/maternal ratio between the placental perfusion model and the in vivo data. Since variation is expected to be high, values <0.1 (limited transfer), $0.1-1$ (transfer) and >1 (fetal accumulation) will be considered as similar between both groups.

Study description

Background summary

The placenta is the most crucial organ in the development of the fetus(1). Via the placenta, the fetus receives oxygen and nutrients, while fetal waste is removed via diffusion and active transport. To fulfill this task, the placenta has a strict separation of the fetal and the maternal circulation. Suboptimal development of the placenta may lead to severe complications of pregnancy, most importantly pre-eclampsia (PE), characterized by elevated blood pressure and proteinuria in the mother, potentially leading to maternal and fetal morbidity and mortality (2, 3). Examination of placentas from PE pregnancies shows structural changes in the placental blood vessels, such as arterial vessel wall thickening and obstruction by atherosclerotic plaques, resulting in increased placental vascular resistance and a reduction in placental blood flow (4-6). The precise aetiology of the clinical symptoms of PE is still largely unknown. However, we and others have demonstrated that changes in the ratio of pro-angiogenic factors produced by the placenta,

probably in response to hypoperfusion, lead to a decrease in vascular endothelial growth factor (VEGF) and an increase in endothelin-1 (ET-1), a strong vasoconstrictor (7). ET-1 is thought to be responsible for the hypertension and nephropathy in PE. ET-1 receptor blockers (ERAs), currently used by patients with pulmonary hypertension, may therefore represent a novel treatment option for PE. However, due to teratogenicity in animal models, ERAs are currently contraindicated during pregnancy. Although suggested from the vascular changes described above, it is currently unknown whether placental drug transfer in general is different in hypertensive pregnancy disorders compared to healthy placentas. To consider ERAs or other treatment options for a clinical study in PE we first need to increase our knowledge about placental drug transfer in general and in PE, which has not been studied before. For this aim we will use a placental perfusion model (METC EMC-prg 1 2016-418). Since direct comparisons between in vivo measurements and data obtained using the model are scarce, we want to compare in vivo data (i.e. the drug concentration in maternal and umbilical blood levels) with predicted data using the ex vivo model.(8) For this purpose, we will use nifedipine as a model drug, since it is used both in patients with gestational hypertension, in patients with PE and in patients without hypertension who are at risk for premature birth.(9-11) Nifedipine is (together with labetalol) used in pregnancy for decades as second line option after methyldopa.(12) Limited PK data suggest that metabolism of nifedipine is faster during pregnancy probably due to induction of CYP3A4/5.(13, 14) Although placental transfer takes place this does not lead to accumulation, however patients with or without hypertensive pregnancy disorders have not been compared previously.(8) (14)

REFERENCES

1. Clifton VL. Review: Sex and the human placenta: mediating differential strategies of fetal growth and survival. *Placenta*. 2010;31 Suppl:S33-9.
2. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. *Lancet*. 2016;387(10022):999-1011.
3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet*. 2010;376(9741):631-44.
4. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. *BJOG*. 2006;113(5):580-9.
5. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*. 2005;308(5728):1592-4.
6. Sankar KD, Bhanu PS, Ramalingam K, Kiran S, Ramakrishna BA. Histomorphological and morphometrical changes of placental terminal villi of normotensive and preeclamptic mothers. *Anat Cell Biol*. 2013;46(4):285-90.
7. Saleh L, Verdonk K, Visser W, van den Meiracker AH, Danser AH. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. *Ther Adv Cardiovasc Dis*. 2016;10(5):282-93.
8. Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. *Clin Pharmacol Ther*. 2011;90(1):67-76.
9. Flenady V, Wojcieszek AM, Papatsonis DN, Stock OM, Murray L, Jardine LA, et

- al. Calcium channel blockers for inhibiting preterm labour and birth. *Cochrane Database Syst Rev*. 2014(6):CD002255.
10. Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. *J Hypertens*. 2014;32(3):454-63.
11. Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med*. 1996;335(4):257-65.
12. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013;122(5):1122-31.
13. Quinney SK, Mohamed AN, Hebert MF, Haas DM, Clark S, Umans JG, et al. A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. *CPT Pharmacometrics Syst Pharmacol*. 2012;1:e2.
14. Filgueira GCO, Filgueira OAS, Carvalho DM, Marques MP, Moises ECD, Duarte G, et al. Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. *Br J Clin Pharmacol*. 2017;83(7):1571-9.
15. Conings S, Amant F, Annaert P, Van Calsteren K. Integration and validation of the ex vivo human placenta perfusion model. *J Pharmacol Toxicol Methods*. 2017;88(Pt 1):25-31.
16. Mathiesen L, Mose T, Morck TJ, Nielsen JK, Nielsen LK, Maroun LL, et al. Quality assessment of a placental perfusion protocol. *Reprod Toxicol*. 2010;30(1):138-46.
17. Nagai M, Ohtani H, Satoh H, Matsuoka S, Hori S, Fujii T, et al. Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing. *Drug Metab Dispos*. 2013;41(12):2124-32.
18. Haas DM, Quinney SK, Clay JM, Renbarger JL, Hebert MF, Clark S, et al. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. *Am J Perinatol*. 2013;30(4):275-81.
19. Silberschmidt AL, Kuhn-Velten WN, Juon AM, Zimmermann R, von Mandach U. Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. *BJOG*. 2008;115(4):480-5.

Study objective

Primary Objective:

To compare the fetal/maternal ratio of nifedipine blood concentrations between pregnancies with and without hypertensive disorders, including preeclampsia.

Secondary Objective:

To compare predicted fetal/maternal drug ratios with observed fetal/maternal drug ratios in pregnancies with and without a hypertensive pregnancy disorder including preeclampsia.

Study design

The study will be a case-control study including both patients with hypertension and suspicion of pre-eclampsia and patients at risk for preterm birth (< 34 weeks of gestation). The study duration will be estimated one year, the time needed to include eight women for each group for placental analysis. Since patients with hypertension are at high risk of development of PE, we will include these patients at the outpatient clinic. The maximum number of extra venepunctures for this study will be two: one trough level in steady state, one just before and one just after delivery. In addition, during regular vein sampling an extra tube will be collected for pharmacokinetic modelling.

Study burden and risks

The procedure involves between three to five additional blood samples taken from the mother dependent on the time between inclusion and delivery. The risk is trivial. There is no direct benefit for the patient.

Contacts

Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

Dr. Molewaterplein 40
Rotterdam 3015GD
NL

Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

Dr. Molewaterplein 40
Rotterdam 3015GD
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

- pregnant
- prescription of nifedipine
- delivery planned in Sophia Children's hospital
- understanding of Dutch / English in speaking and reading
- written informed consent

Exclusion criteria

- not unwilling or unable to give written informed consent
- multiple pregnancy
- infectious diseases (e.g. HIV, hepatitis B, ZIKA) for laboratory safety
- fetal congenital abnormalities
- manual placenta removal

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 07-03-2019

Enrollment: 48

Type: Actual

Ethics review

Approved WMO

Date: 28-09-2018

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL65425.078.18